Physicochemical Properties
| Molecular Formula | C35H56O8 |
| Molecular Weight | 604.8144 |
| Exact Mass | 604.397 |
| CAS # | 35286-59-0 |
| PubChem CID | 71773126 |
| Appearance | White to off-white solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 716.2±60.0 °C at 760 mmHg |
| Melting Point | 260-263℃ |
| Flash Point | 218.6±26.4 °C |
| Vapour Pressure | 0.0±5.2 mmHg at 25°C |
| Index of Refraction | 1.588 |
| LogP | 7.68 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 43 |
| Complexity | 1170 |
| Defined Atom Stereocenter Count | 14 |
| SMILES | C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O |
| InChi Key | MFIXLWYJTVEVGO-YHGWSDCJSA-N |
| InChi Code | InChI=1S/C35H56O8/c1-19-10-15-35(29(39)40)17-16-32(5)20(27(35)34(19,7)41)8-9-23-31(4)13-12-24(30(2,3)22(31)11-14-33(23,32)6)43-28-26(38)25(37)21(36)18-42-28/h8,19,21-28,36-38,41H,9-18H2,1-7H3,(H,39,40)/t19-,21+,22+,23-,24+,25+,26-,27-,28+,31+,32-,33-,34-,35+/m1/s1 |
| Chemical Name | (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In a dose-dependent manner, purpuroside II (10–60 μM; 24 h and 48 h) inhibits the growth of MDA-MB-435 cells. Purpurin II's half-life at 24 and 48 hours is 5.92 μM and 4.74 μM, respectively [1]. In MDA-MB-435 cells, purpuroside II (5–25 μM) causes G0/G1 and S phase arrest for a full day [1]. In MDA-MB-435 cells, ziyuglycoside II (5–25 μM; 24 h) markedly raised p53 and p21 expression. Ziyuglycoside II (5–25 μM; given to MDA-MB-435 cells for 24 hours). The simulation rate is affected by it[1]. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 10, 20, 30, 40, 50, 60 μM Incubation Duration: 24 hrs (hours) and 48 hrs (hours) Experimental Results: IC50 at 24 hrs (hours) and 48 hrs (hours) are 5.92 μM respectively and 4.74 μM. Cell cycle analysis[1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 5, 10, 25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of G0/G1 and S phase arrest. Apoptosis analysis [1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 5, 10, 25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with the control, the cell apoptosis rate increased Dramatically. Western Blot Analysis[1] Cell Types: MDA-MB-435 Cell Tested Concentrations: 5, 10, 25 μM Incubation Duration: 24 hrs (hours) Experimental Results: Treatment resulted in increased expression of p53 and p21. |
| References |
[1]. Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway. Int J Mol Sci. 2013 Sep 3;14(9):18041-55. [2]. Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells. Toxicol Lett. 2014 May 16;227(1):65-73. |
| Additional Infomation | ziyuglycoside II has been reported in Sanguisorba officinalis with data available. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~82.67 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.83 mg/mL (1.37 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.83 mg/mL (1.37 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.83 mg/mL (1.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6534 mL | 8.2671 mL | 16.5341 mL | |
| 5 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL | |
| 10 mM | 0.1653 mL | 0.8267 mL | 1.6534 mL |